[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369033-105":59,"doc-detail-369033-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","automated-machine-learning-based-unenhanced-radiomics-for-identification-of-her2-low-breast-cancers-using-diffusion-weighted-imaging","Automated machine learning-based unenhanced radiomics for identification of HER2-low breast cancers using diffusion-weighted imaging","","Antibody-drug conjugate development requires precise identification of human epidermal growth factor receptor 2 (HER2)-low breast cancers. The study develops an automated machine learning model using unenhanced apparent diffusion coefficient (ADC)-based radiomics from diffusion-weighted imaging to distinguish HER2-zero from HER2-low/positive breast cancers, and to separate HER2-zero from HER2-low breast cancers. A total of 169 invasive breast cancer patients were included, extracting 1200 radiomics features and 11 clinicopathologic features per lesion. An automated pipeline built with PyCaret evaluated 13 models using AUC and then validated the optimal model internally, with statistical comparisons via t-tests, Mann-Whitney U tests, and Chi-square tests. The best-performing models achieved AUCs of 0.75 and 0.79/0.82 across relevant classification tasks, supporting feasibility and potential value. ",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/automated-machine-learning-based-unenhanced-radiomics-for-identification-of-her2-low-breast-cancers-using-diffusion-weighted-imaging/369033/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/automated-machine-learning-based-unenhanced-radiomics-for-identification-of-her2-low-breast-cancers-using-diffusion-weighted-imaging/369033.png","ImageObject",300,407,{"name":92,"@type":93},"hdkawk","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What problem does the study address for HER2-low breast cancer?","Question",{"text":113,"@type":114},"It targets the need for accurate identification of HER2-low breast cancers to support antibody-drug conjugate eligibility, specifically separating HER2-zero from HER2-low/positive and from HER2-low.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How was the radiomics model built and evaluated?",{"text":118,"@type":114},"The study extracted 1200 ADC-based radiomics features and 11 clinicopathologic features per lesion, then used a PyCaret automated machine learning pipeline to train and compare 13 models, selecting the best by AUC and validating it internally.",{"name":120,"@type":111,"acceptedAnswer":121},"Which machine learning model performed best in validation?",{"text":122,"@type":114},"For HER2-zero vs HER2-low, the Gradient Boosting Classifier achieved an AUC of 0.75 in the validation cohort. For HER2-zero vs HER2-low/positive, Random Forest was optimal with an AUC of 0.82.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},369033,1790232402,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":105,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},3985747859855,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Li etal. BMC Cancer (2026) 26:66 BMC Cancer  \n[https://doi.org/10.1186/s12885-025-14198-6](https://doi.org/10.1186/s12885-025-14198-6)  \nRESEARCH Open Access  \nAutomated machine learning-based unenhanced radiomics for identification of HER2-low breast cancers using diffusionweighted imaging  \nXue Li 1,2, Chunmei Li 1,2, Lei Jiang 1,2, Dandan Zheng3, Song Tian3 and Min Chen 1,2*  \nAbstract  \nRationale and objectives The development of new antibody-drug conjugates necessitates precise identification of human epidermal growth factor receptor 2 (HER2)-low breast cancers. This study explores the potential application of an automated machine learning model to develop unenhanced apparent diffusion coefficient (ADC)-based radiomics for distinguishing between HER2-zero and HER2-low/ positive breast cancers, as well as HER2-zero and HER2-low breast cancers.  \nMaterials and methods This study included 169 patients with invasive breast cancer (27 HER2-zero, 96 HER2-low and 46 HER2-positive) . For each lesion, 1200 radiomics features and 11 clinicopathologic features were extracted. An automated machine learning pipeline was constructed using PyCaret for two binary classifications: HER2-zero versus HER2-low and HER2-zero versus HER2-low/ positive breast cancers. The performance of 13 machine learning models was assessed based on the training cohort and was compared using the area under the curve (AUC) to obtain the optimal model. This optimal model was subsequently validated using an internal validation cohort. Statistical analyses included Students’ t-tests, Mann-Whitney U tests or Chi-Square tests. The performance of the best model was evaluated using accuracy, AUC, sensitivity, positive predictive value and F1 score.  \nResults In distinguishing HER2-zero from HER2-low breast cancers, the Gradient Boosting Classifier exhibited superior classification performance with an AUC of 0.75 in the validation cohort. The Random Forest Classifier (RF) exhibited the best performance for the clinical-radiomics model, achieving an AUC of 0.79. For differentiating HER2-zero from HER2-low/ positive breast cancers, RF was optimal for both radiomics and radiomics-clinicopathologic models, each achieving an AUC of 0.82 in the validation cohort.  \nConclusion The application of automated machine learning with ADC-based radiomics for the identification of HER2-low breast cancers is both feasible and advantageous.  \nKeywords Magnetic resonance imaging, Machine learning, Breast neoplasms, Receptor, ErbB-2, Diffusion-weighted imaging  \n*Correspondence: Min Chen[cjr.chenmin@vip.163.com](cjr.chenmin@vip.163.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/l](vecommons.org/l)icenses/by-nc-nd/4.0/.  \nLi et al. BMC Cancer (2026) 26:66  \nIntroduction  \nApproximately 50% of human epidermal growth factor receptor 2 (HER2)-negative breast cancers exhibit HER2-low expression, characterised by an immunohistochemistry (IHC) ","cbCaiclnCRnpdjdU","https://ap.wps.com/l/cbCaiclnCRnpdjdU","pdf",3281358,"English","# Abstract\n## Rationale and objectives\n## Materials and methods\n## Results\n## Conclusion\n# Introduction","[{\"question\":\"What problem does the study address for HER2-low breast cancer?\",\"answer\":\"It targets the need for accurate identification of HER2-low breast cancers to support antibody-drug conjugate eligibility, specifically separating HER2-zero from HER2-low/positive and from HER2-low.\"},{\"question\":\"How was the radiomics model built and evaluated?\",\"answer\":\"The study extracted 1200 ADC-based radiomics features and 11 clinicopathologic features per lesion, then used a PyCaret automated machine learning pipeline to train and compare 13 models, selecting the best by AUC and validating it internally.\"},{\"question\":\"Which machine learning model performed best in validation?\",\"answer\":\"For HER2-zero vs HER2-low, the Gradient Boosting Classifier achieved an AUC of 0.75 in the validation cohort. For HER2-zero vs HER2-low/positive, Random Forest was optimal with an AUC of 0.82.\"}]","Automated machine learning-based unenhanced radiomics for identification of HER2-low breast cancers using diffusion-weighted imaging | PDF",1790180251,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/36473690dd0b54abe09ffa2e5357e7e9.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/95b7474d16d9f9f689c4800372280445.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/26638557612971f969fc362139a167f0.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/193bdb806b56c2c43c10d56a1c750b16.webp",980,1306]